With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Even years later, patients whose symptoms were initially dismissed experience distrust and uncertainty with clinicians.